ALPS Medical Breakthroughs ETF (SBIO) Dividend Yield, History & Forecast

ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund (ETF) listed on the New York Stock Exchange Arca. The most recent ex-dividend date was December 19, 2024, with payment scheduled for December 26, 2024. market capitalization is approximately $185M.

SBIO fund composition

SBIO holds 103 positions, with 35.5% of assets in its ten largest. It charges an expense ratio of 0.50%, and manages $187.0M.

Top 10 holdings

HoldingWeight
CRNXCrinetics Pharmaceuticals Inc.4.59%
ORKAOruka Therapeutics Inc.4.43%
APGEApogee Therapeutics Inc.4.29%
CGONCG oncology Inc.3.82%
MANEVeraDermics Inc.3.75%
TVTXTravere Therapeutics Inc.3.13%
DNTHDianthus Therapeutics Inc.3.11%
DFTXDefinium Therapeutics Inc.3.02%
EWTXEdgewise Therapeutics Inc.2.75%
RLAYRelay Therapeutics Inc.2.57%

Sector allocation

Healthcare100.0%

Frequently Asked Questions about ALPS Medical Breakthroughs ETF (SBIO)

When does ALPS Medical Breakthroughs ETF pay distributions?
The most recent ex-dividend date was December 19, 2024. The next scheduled dividend payment date is December 26, 2024.
How many years has ALPS Medical Breakthroughs ETF increased its dividend?
ALPS Medical Breakthroughs ETF (SBIO) has increased its dividend for 1 consecutive year.
What does ALPS Medical Breakthroughs ETF invest in?
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.